SynthesisPloS one2025
Association of triglyceride glucose-body mass index (TyG-BMI) with metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis.
Synthesis in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The triglyceride glucose-body mass index and the risk of gestational diabetes mellitus: a systematic review and meta-analysis.Frontiers in nutrition · 2026Pooled it
- Triglyceride glucose-body mass index as a practical screening tool for metabolic dysfunction-associated steatotic liver disease in older adults: A community-based cohort study.Asia Pacific journal of clinical nutrition · 2026Article
- TyG-BMI as a Marker of Metabolic Status and Its Association with Bone Quality and Mineral Metabolism: A Sex-Specific Analysis.Journal of clinical medicine · 2026Article
- Association Between Triglyceride-Glucose Index and Risk of Cancer: A Systematic Review and Meta-Analysis.Journal of personalized medicine · 2026Review
- Association of Body Roundness Index, Lipid Accumulation Product, and Triglyceride-Glucose Index With Psoriasis: A Systematic Review of Observational Studies.Health science reports · 2026Review
- The association of TyG-BMI with MAFLD and liver fibrosis: a cross-sectional study.Scientific reports · 2026Article
- Clinical Utility of the Triglyceride-Glucose Index in Assessing Hepatic Steatosis Severity Within the MASLD Spectrum.Diagnostics (Basel, Switzerland) · 2026Article
- Diagnostic performance of TyG-related indices for MAFLD screening in older adults at moderate altitude: TyG-BMI showed the highest discriminatory ability.BMC gastroenterology · 2026Article
- The development and evaluation of nine non-conventional lipid parameters for metabolic dysfunction-associated fatty liver disease in Chinese medical health examination adults: a single-center retrospective study.Frontiers in nutrition · 2026Article
- Gut Microbiota-Metabolite Alterations Associated with Early Metabolic Dysfunction and Hepatic Steatosis in Adolescents.Computational and structural biotechnology journal · 2026Article
- Prevalence and determinants of general and abdominal obesity and overweight among older Iranian adults using 2016 and 2021 STEPS surveys.Scientific reports · 2025Article
- Predictive Value and Correlation Study of HOMA2 IR-CP and TyG-BMI for Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients with Type 2 Diabetes Mellitus.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTyG-BMI has been proposed as a marker of insulin resistance in metabolic-associated fatty liver disease, but its clinical utility remains uncertain. This study aims to evaluate the association between TyG-BMI and metabolic dysfunction-associated steatotic liver disease (MASLD) through a systematic review and meta-analysis, focusing on the diagnostic performance across different subgroups.
methodsA comprehensive literature search was conducted in PubMed, Scopus, Embase, and Web of Science up to January 20, 2025. Studies evaluating the relationship between TyG-BMI and MASLD in adults were included. A random-effects model was employed to pool effect sizes, and subgroup analyses were conducted based on sex, disease definition, and population type.
resultsThirty-five studies with 339,087 participants were included. The pooled mean difference for TyG-BMI between MASLD and non-MASLD groups was 42.72 (95% CI: 35.93-49.51; p < 0.0001). Subgroup analysis revealed higher mean differences in the metabolic-associated fatty liver disease (MAFLD) group (49.56, 95% CI: 39.38-59.74) compared to non-alcoholic fatty liver disease ase (NAFLD) (34.68, 95% CI: 28.45-40.91). The odds ratio per one-unit increment of the TyG-BMI was 1.05 (95% CI: 1.03-1.08). Sensitivity for TyG-BMI in diagnosing MASLD was 0.79 (95% CI: 0.73-0.84), and specificity was 0.76 (95% CI: 0.71-0.80). The pooled area under the curve (AUC) for TyG-BMI was 0.83 (95% CI: 0.81-0.86), with better performance in females (0.88) compared to males (0.83). Subgroup analysis by disease definition showed a higher AUC for MAFLD (0.87) compared to NAFLD (0.81).
conclusionTyG-BMI is a promising diagnostic marker for MASLD, with higher diagnostic performance in MAFLD and among females. Further studies are needed to confirm these findings in diverse populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.